SILO Pharma Inc(SILO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -5.34 | Insider Own | 9.75% | Shs Outstand | 1.6M | Perf Week | 4.24% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 1.4M | Perf Month | -18% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | - | Inst Own | 6.95% | Short Float | 1.54% | Perf Quarter | -71.53% |
| Income | -0.00B | P/S | 39.16 | EPS this Y | - | Inst Trans | 0.86% | Short Ratio | 0.23 | Perf Half Y | -81.98% |
| Sales | 0.00B | P/B | 0.28 | EPS next 5Y | - | ROA | -70.96% | Short Interest | 0.02M | Perf YTD | -75.88% |
| Book/sh | 4.33 | P/C | 0.36 | EPS past 3/5Y | 33.45% 26.52% | ROE | -91.23% | 52W High | -88.2% ($10.43) | Perf Year | -85.2% |
| Cash/sh | 3.41 | P/FCF | - | Sales past 3/5Y | - | ROIC | -91.52% | 52W Low | 11.82% ($1.10) | Perf 3Y | -94.31% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 65.23% | Gross Margin | -1329.43% | Volatility(W/M) | 7.06% 7.5% | Perf 5Y | -99.18% |
| Dividend TTM | - | EV/Sales | -69.44 | Sales Y/Y TTM | -25% | Oper. Margin | -8250.46% | ATR (14) | 0.11 | Perf 10Y | -99.84% |
| Dividend Ex-Date | - | Quick Ratio | 5.36 | EPS Q/Q | 73.65% | Profit Margin | -8269.53% | RSI (14) | 34.16 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.36 | Sales Q/Q | -100% | SMA20 | -4.47% ($1.29) | Beta | 0.9 | Target Price | $150 |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | -29.99% ($1.76) | Rel Volume | 0.13 | Prev Close | $1.25 |
| Employees | 3 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -73.04% ($4.56) | Avg Volume(3M) | 0.10M | Price | $1.23 |
| IPO | 2014/5/13 | Option/Short | No/Yes | Trades | 96 | Volume | 12,044 | Change | -1.6% |
A US clinical-stage biotech that develops neuroscience-based novel drug candidates targeting stress-related mental illnesses (PTSD and anxiety) and chronic pain. Its lead pipelines include SPC-15, an intranasal spray for PTSD, and SP-26, a ketamine implant for chronic pain, along with preclinical assets for Alzheimer's disease and multiple sclerosis. It is a micro-cap company listed on the Nasdaq.
Over the past 1 year, on the lower side
88% below its 1-year high.
Traded less than usual. That is 13% of its average volume.
SILO has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $3,916. Peers typically go for $1,010. Compared with its own 1-year average, it is 98% cheaper now.
Tap to view numbers
Not enough quarters to judge yet
Only 2 quarter(s) reported, so no grade yet.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.2%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 7.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
PSIL AdvisorShares Psychedelics ETF 0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #576 of 597 in the industry
Based on market cap of $2M.
FAQ
What kind of company is SILO?
SILO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SILO?
The market cap of SILO is approximately $2M, ranking 5,806 within its sector.
What is the 52-week high and low for SILO?
SILO has recorded a 52-week high of $10.43 and a low of $1.10.
